Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT exon11 KIT V654A |
| Therapy | Imatinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT exon11 KIT V654A | gastrointestinal stromal tumor | predicted - resistant | Imatinib | Case Reports/Case Series | Actionable | In a clinical study, 65.8% (25/38) of patients with a gastrointestinal stromal tumor harboring a primary KIT mutation in exon 11 or exon 9 progressed on treatment with Gleevec (imatinib) and 10 of the 25 patients were found to have acquired a secondary mutation in exon 13, KIT V654A (PMID: 23456621). | 23456621 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (23456621) | Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. | Full reference... |